May 20th, 2026 | 08:30 CEST
Disruption in the Agricultural Sector: Why Corteva and Deere & Company Are Keeping an Eye on MustGrow Biologics
Created and published on behalf of MustGrow Biologics Corp.
High energy prices, soil degradation, and consumer preference for organic products—the growing pressure on traditional agricultural chemicals poses an existential challenge to established market leaders. Those who do not embrace biological alternatives now risk falling behind due to growing regulatory requirements and increasing resistance. Driven by historically high energy prices, which make the production of conventional fertilizers more expensive, agricultural businesses are facing cost pressures. This economic predicament is becoming a catalyst for innovation: major corporations are investing billions in digital solutions and biologically active ingredients. We shed light on this trend and introduce exciting companies.
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
MUSTGROW BIOLOGICS CORP. | CA62822A1030 | TSXV: MGRO , OTCQB: MGROF , CORTEVA INC. DL -_01 | US22052L1044 , DEERE CO. DL 1 | US2441991054
Table of contents:
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
Corteva: Strategic Restructuring Ahead of the Major Split
The US industry giant Corteva demonstrates just how aggressively the agricultural industry is driving structural change. The company is responding to dwindling sales with a targeted acquisition strategy in the biologics segment. Through the targeted acquisitions of the Spanish microbiology specialist Symborg for USD 370 million and the Texas-based Stoller Group for USD 1.2 billion, the corporation has invested a total of over USD 1.5 billion. The goal is to secure market leadership in a sector that, according to market forecasts by Fortune Business Insights, is growing nearly three times as fast as traditional crop protection.
Corteva is preparing to split into two independent, publicly traded units in the fourth quarter of 2026. The goal: to reduce valuation discounts. While the entire seed and genetics business will be spun off under the name SpinCo, the high-margin biologicals and crop protection business will remain within the New Corteva unit. New Corteva will operate as a highly specialized company in the future and aims to further increase its operating EBITDA margin, which was already over 22% in fiscal year 2025. Management has great confidence in this strategy. Board member Janet Plaut Giesselman converted her entire cash compensation into shares. With a market capitalization of around USD 55 billion and strong momentum near the 52-week high, the stock price indicates that the outlook is positive—thanks in part to investments in Biologicals.
Deere & Company: From Hardware Manufacturer to Digital Platform
The fact that digitalization has also reached the field is demonstrated by the global tractor market leader, Deere & Company. The long-established company is gradually transforming itself from a pure machinery manufacturer into a technology-driven platform provider. The hardware—such as the John Deere 8R autonomous tractor or the See & Spray systems—primarily serves as a vehicle for digital services. Through the John Deere Operations Center, the primary source of revenue is gradually shifting toward recurring software revenue and digital subscriptions. Through a deeply integrated digital partnership with Corteva, John Deere feeds scientific data and precise seeding recipes directly into the onboard computers of autonomous systems. The automated workflow eliminates manual input errors: as soon as a machine crosses the field boundary, the seeder instantly adjusts to the precisely specified, variable seeding rates and hybrid varieties. Although sales in the large machinery segment fell by 12% in fiscal year 2025, the high margin of the Precision Ag division is stabilizing the stock price. This demonstrates that innovation pays off.
MustGrow Biologics: The Highly Efficient Mustard Seed Platform in Focus Among Major Players
In the midst of a rapidly changing agricultural landscape, the research-driven agrotech company MustGrow Biologics is positioning itself as an innovator and potential partner for major industry players. The purely IP-based business model relies on outsourcing production to international contract manufacturers, thereby avoiding the need for capital-intensive in-house production facilities. MustGrow controls a portfolio of approximately 108 granted and pending patents that enable the commercial application of the mustard seed's natural defence mechanisms.
The company's core product is the biological fertilizer TerraSante™, which reactivates the soil's beneficial microbiome and delivers outstanding efficiency levels in field trials. Commercial potato cultivation trials in Washington State demonstrate that the use of TerraSante™, according to the grower, generated a significant return on investment. TerraSante™ is complemented by the liquid extract pre-registered product TerraMG™ for biological pest control.
Conclusion: Takeover Bet Thanks to Valuation Gap
The valuation does not yet adequately reflect the enormous potential of MustGrow's products in the current market environment. While major players like Corteva or Deere face constant pressure to innovate, MustGrow Biologics' stock is trading near its 52-week low at around CAD 0.55. This corresponds to a market capitalization of just CAD 33 million. In contrast, the global market for agricultural biologics is projected by MarketsandMarkets to grow to as much as USD 44 billion by the period 2030 to 2032. The recent transactions by MustGrow COO Colin Bletsky and CEO Corey Giasson, who exercised a large number of options to increase their direct shareholdings, also point in the right direction. Investors looking for opportunity-driven investments in the agricultural sector may want to take a closer look at MustGrow's stock.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
